【Press Release】CAC Croit and Mitsubishi Tanabe Pharma Conclude a Basic Agreement on the “QualityLead” Program
A compound library-sharing program to support innovative “All Japan” drug discovery
Tokyo, December 20, 2018 – CAC Croit announced the conclusion of a basic agreement on a framework of the QualityLead program with Tanabe Mitsubishi Pharma Corporation. The QualityLead program is CAC Croit’s compound library-sharing program, which has been selected as one of Japan Agency for Medical Research and Development (AMED)’s Cycle Innovation for Clinical Empowerment (CiCLE) programs.
In the QualityLead program, CAC Croit will provide a platform for integrated management of compound libraries from pharmaceutical companies, from library management through to plate production, for drug discovery research. This will help to reduce compound management costs in large capital investments and maintenance fees for the pharmaceutical companies. By establishing this compound library-sharing platform and offering it to pharmaceutical companies, academia and bio-venture companies, CAC Croit will strengthen industry-industry and industry-government-academia collaboration, hence also enhancing the “All Japan” drug discovery systems to develop innovative Japanese drugs.
The platform project in the QualityLead program was selected as one of Japan Agency for Medical Research and Development (AMED)’s Cycle Innovation for Clinical Empowerment (CiCLE) programs in January 2018.
Benefits of QualityLead program
- No need for pharmaceutical companies to individually manage compounds. This will significantly reduce capital investment and fixed costs, and enhance productivity of industry-wide R&D.
- The use of the compound library-sharing platform by pharmaceutical and bio-venture companies will help to expand the potential of innovative drug discovery.
- Academia can easily access corporate libraries. Matching academia’s drug discovery seeds with pharmaceutical companies’ needs increases opportunities to accelerate drug discovery.
- By building a database from shared compound information, researchers can utilize the database for data mining and lead to the success of artificial intelligence (AI) drug discovery.
CAC Croit intends to increase the number of companies sharing compounds and develop new services in order to accelerate innovative Japanese drug discovery utilizing the QualityLead program.
Through these activities, CAC Croit will contribute to the growth of the pharmaceutical industry through innovation to improve the efficiency of drug discovery by combining our skills in IT and the CRO industry.
In the past, compound libraries had been considered too valuable an asset to be shared outside of each pharmaceutical company. In recent years, the same companies have started sharing their libraries, but have only been able to share limited items due to facing obstacles in that different companies utilize different management systems, equipment and methods. For these reasons, CAC Croit, recognized as a pioneer in CRO and IT integration, started the QualityLead program to offer compound library management and automated storage systems, and to deliver an integrated service from library management through to plate production. CAC Croit thus facilitates the sharing of compound libraries between pharmaceutical companies, academia, and bio-venture companies.